155 related articles for article (PubMed ID: 11014408)
1. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
6. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
[TBL] [Abstract][Full Text] [Related]
7. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
11. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).
Joulia JM; Pinguet F; Ychou M; Duffour J; Topart D; Grosse PY; Astre C; Bressolle F
Anticancer Res; 1997; 17(4A):2727-30. PubMed ID: 9252705
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
Ueno H; Okada S; Okusaka T; Ikeda M; Kuriyama H
Cancer Chemother Pharmacol; 2002 Feb; 49(2):155-60. PubMed ID: 11862430
[TBL] [Abstract][Full Text] [Related]
18. Puzzles in the clinical pharmacokinetics of fluorouracil.
Desoize B; Bouche O; Berthiot G; Coninx P
Anticancer Res; 1998; 18(6B):4607-10. PubMed ID: 9891526
[TBL] [Abstract][Full Text] [Related]
19. Will we ever be ready for blood level-guided therapy?
Walko CM; McLeod HL
J Clin Oncol; 2008 May; 26(13):2078-9. PubMed ID: 18445837
[No Abstract] [Full Text] [Related]
20. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]